Pharmaceuticals, Biotechnology and Life Sciences
Takeda’s approval makes Entyvio the only maintenance therapy approved across Europe with both intravenous and subcutaneous formulation options for adult patients with ulcerative colitis or Crohn’s disease.
TiGenix’s result from study of Xx601 treatment for Chron’s disease has also been published in one of the leading scientific…
Belgian-headquartered biopharmaceutical company TiGenix has received positive feedback from the U.S. Food and Drug Administration (FDA) for its improved phase III trial for the treatment of complex perianal fistulas in Crohn’s disease patients.